Erythromycin dermal delivery by MoS2 nanoflakes

• Published in: Journal of pharmaceutical investigation Vol. 51; no. 6; pp. 691 - 700
• Main Authors: Abareshi, Afsaneh, Samadi, Naghmeh, Houshiar, Mahboubeh, Nafisi, Shohreh, Maibach, Howard I.
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.11.2021; 한국약제학회
• Subjects: Biomedical and Life Sciences; Biomedicine; Original Article; 약학; MoS; Photothermal effect; Topical drug delivery; Erythromycin; nanoflakes
• ISSN: 2093-5552; 2093-6214
• DOI: 10.1007/s40005-021-00539-7

Objective This study developed a novel MoS 2 nanoflakes platform for the drug delivery (erythromycin) into the skin. Method MoS 2 nanoflakes were synthesized using one-step hydrothermal method and characterized for the structural and optical properties by transmission electron microscopy (TEM), energy-dispersive X-ray (EDX), X-ray diffraction (XRD), Raman spectroscopy, Fourier transform infrared (FTIR), and Ultraviolet–visible (UV–Vis) spectroscopies. Then, the photothermal experiment was performed for the MoS 2 sample with the concentrations (100, 200, 300, and 400 ppm). Results The highest photothermal heat was produced in the sample with 400 ppm concentration. Erythromycin loaded MoS 2 nanoflakes (ERY/MoS 2 ) were successfully prepared by the different ratios of ERY to MoS 2 nanoflakes (1:1, 2:1, 3:1, 4:1, and 5:1). ERY/MoS 2 with the ratio of 5:1 showed the highest entrapment efficiency (EE%) (62.8%) which was selected as the optimized formulation. The sample was further studied for in-vitro ERY release and ex-vivo skin permeation patterns with and without the laser irradiation (808 nm). Results indicated that in the presence of near-infrared (NIR) laser radiation (1 W/cm 2 ), the optimized ERY/MoS 2 sample showed a controlled drug release of 47.3% through a silicon membrane which reached a sustained flux of 201.83 μg/cm 2 through human skin after 24 h. Conclusion MoS 2 nanoflakes with an appropriate sustained release pattern were suggested as suitable carriers in the dermal drug delivery system for ERY.